featured
Efficacy of Osimertinib + Bevacizumab vs Osimertinib in EGFR-Mutated NSCLC Previously Treated With EGFR-TKI
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
JAMA Oncol 2021 Jan 07;[EPub Ahead of Print], H Akamatsu, Y Toi, H Hayashi, D Fujimoto, M Tachihara, N Furuya, S Otani, J Shimizu, N Katakami, K Azuma, N Miura, K Nishino, S Hara, S Teraoka, S Morita, K Nakagawa, N YamamotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.